Search research articles
Contact Us
Filters
Showing results (101-110 of 114) with videos related to
Page
of 12
Sort By:
Parkinsonism & Related Disorders
|
October 9, 2013
Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens
F Mancini, C Comi, G D Oggioni, et al.
The Journal of Clinical Psychiatry
|
October 8, 2025
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial
Clotilde Guidetti, George I Papakostas, Luca Pani, et al.
Pain
|
October 7, 2003
QTc interval prolongation associated with intravenous methadone
Craig A Kornick, Michael J Kilborn, Juan Santiago-Palma, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Stephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
The American Journal of Psychiatry
|
October 27, 1997
Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders
P D Nowell, D J Buysse, C F Reynolds, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 26, 2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Ezio Bettini, Stephen M Stahl, Sara De Martin, et al.
Journal of Wound Care
|
June 12, 2016
Recommendations for the management of biofilm: a consensus document
T Bianchi, R D Wolcott, A Peghetti, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology
|
February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants
Clotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry
|
February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
Maurizio Fava, Luca Pani, Sara De Martin, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 114) with videos related to
Sort By:
Page
of 12
Parkinsonism & Related Disorders
|
October 9, 2013
Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens
F Mancini, C Comi, G D Oggioni, et al.
The Journal of Clinical Psychiatry
|
October 8, 2025
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis: An Exploratory Post Hoc Analysis From a Phase 3 Randomized Controlled Trial
Clotilde Guidetti, George I Papakostas, Luca Pani, et al.
Pain
|
October 7, 2003
QTc interval prolongation associated with intravenous methadone
Craig A Kornick, Michael J Kilborn, Juan Santiago-Palma, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Stephen M Stahl, Sara De Martin, Andrea Mattarei, et al.
The American Journal of Psychiatry
|
October 27, 1997
Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders
P D Nowell, D J Buysse, C F Reynolds, et al.
Pharmaceuticals (Basel, Switzerland)
|
August 26, 2022
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Ezio Bettini, Stephen M Stahl, Sara De Martin, et al.
Journal of Wound Care
|
June 12, 2016
Recommendations for the management of biofilm: a consensus document
T Bianchi, R D Wolcott, A Peghetti, et al.
European Archives of Psychiatry and Clinical Neuroscience
|
March 8, 2023
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Maurizio Fava, Stephen M Stahl, Sara De Martin, et al.
International Clinical Psychopharmacology
|
February 27, 2026
Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants
Clotilde Guidetti, George I Papakostas, Steven Stahl, et al.
The Journal of Clinical Psychiatry
|
February 25, 2025
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study
Maurizio Fava, Luca Pani, Sara De Martin, et al.
Page
of 12